Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages : The PSERENADE project

dc.contributor.authorThe PSERENADE Team
dc.contributor.departmentFaculty of Medicine
dc.date.accessioned2025-11-20T09:50:32Z
dc.date.available2025-11-20T09:50:32Z
dc.date.issued2025-03
dc.descriptionPublisher Copyright: © 2025 The Author(s)en
dc.description.abstractBackground: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally. Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally. Site-specific meningitis incidence rate ratios (IRRs) comparing pre-PCV incidence to each year post-PCV10/13 were estimated by age (<5, 5–17 and ≥18 years) using Bayesian multi-level mixed effects Poisson regression, accounting for pre-PCV trends. All-site weighted average IRRs were estimated using linear mixed-effects regression stratified by age, product (PCV10 or PCV13) and prior PCV7 impact (none, moderate, or substantial). Changes in pneumococcal meningitis incidence were estimated overall and for product-specific vaccine-types and non-PCV13-types. Results: Analyses included 10,168 cases <5 y from PCV13 sites and 2849 from PCV10 sites, 3711 and 1549 for 5–17 y and 29,187 and 5653 for ≥18 y from 42 surveillance sites (30 PCV13, 12 PCV10, 2 PCV10/13) in 30 countries, primarily high-income (84%). Six years after PCV10/PCV13 introduction, pneumococcal meningitis declined 48–74% across products and PCV7 impact strata for children <5 y, 35–62% for 5–17 y and 0–36% for ≥18 y. Impact against PCV10-types at PCV10 sites, and PCV13-types at PCV13 sites was high for all age groups (<5 y: 96–100%; 5–17 y: 77–85%; ≥18 y: 73–85%). After switching from PCV7 to PCV10/13, increases in non-PCV13-types were generally low to none for all age groups. Conclusion: Pneumococcal meningitis declined in all age groups following PCV10/PCV13 introduction. Plateaus in non-PCV13-type meningitis suggest less replacement than for all IPD. Data from meningitis belt and high-burden settings were limited.en
dc.description.versionPeer revieweden
dc.format.extent4130547
dc.format.extent
dc.identifier.citationThe PSERENADE Team 2025, 'Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages : The PSERENADE project', Journal of Infection, vol. 90, no. 3, 106426. https://doi.org/10.1016/j.jinf.2025.106426en
dc.identifier.doi10.1016/j.jinf.2025.106426
dc.identifier.issn0163-4453
dc.identifier.other236540201
dc.identifier.othera22e63bd-f1b2-454f-96de-23ad42b867f5
dc.identifier.other85217119857
dc.identifier.other39864526
dc.identifier.urihttps://hdl.handle.net/20.500.11815/7794
dc.language.isoen
dc.relation.ispartofseriesJournal of Infection; 90(3)en
dc.relation.urlhttps://www.scopus.com/pages/publications/85217119857en
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectIncidenceen
dc.subjectIndirect protectionen
dc.subjectPneumococcal conjugate vaccinesen
dc.subjectPneumococcal meningitisen
dc.subjectSerotype replacementen
dc.subjectSerotypesen
dc.subjectVaccine impacten
dc.subjectsýklafræðien
dc.subjectMicrobiology (medical)en
dc.subjectInfectious Diseasesen
dc.titleGlobal impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages : The PSERENADE projecten
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
1-s2.0-S0163445325000209-main.pdf
Stærð:
3.94 MB
Snið:
Adobe Portable Document Format

Undirflokkur